TNK2 and prostate carcinoma: The inhibition of the Ack1-mediated phosphorylation of the C-terminal Src kinase has been found to counteract prostate cancer resistance to immune checkpoint blockade [60] and to overcome the acquired resistance of EGFR mutant non-small-cell lung cancer (NSCLC) cells to Osimertinib, the inhibitor of EGFR [64].